Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UF-KURE19 in Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
NCT07713459Phase 2Not yet recruiting
- Sponsor
- Kure.ai
- Start
- Aug 2026
- Primary completion
- Aug 2029
01
Overview
Phase 2, open-label trial of UF-KURE19 in non-Hodgkin lymphoma (NHL) (2 arms), sponsored by Kure.ai. Primary endpoint: Complete Response Rate at 90 days. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
UF-KURE19
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT07713459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07713459.